Analysis of Fucosylated Human Milk Trisaccharides in Biotechnological Context Using Genetically Encoded Biosensors
April 13th, 2019
We describe here the high-throughput detection and quantification of fucosylated human milk oligosaccharides (HMOs) using a whole-cell biosensor. We also demonstrate here, the adaptation of this platform towards analysis of HMO production strains, focusing on improving the signal to noise ratio.
Overview
This article presents a method for the high-throughput detection and quantification of fucosylated human milk oligosaccharides (HMOs) using a whole-cell biosensor. The approach aims to simplify and accelerate the quantification and characterization of HMOs, addressing key questions about product quantity and carbohydrate linkage.
Key Study Components
Area of Science
- Biochemistry
- Analytical Chemistry
- Food Science
Background
- Human milk oligosaccharides are important for infant health.
- Current methods for HMO analysis are time-consuming and complex.
- High-throughput screening can enhance efficiency in HMO research.
- Understanding HMO production can lead to better nutritional products.
Purpose of Study
- To develop a high-throughput method for HMO detection.
- To improve the signal-to-noise ratio in HMO quantification.
- To facilitate the analysis of HMO production strains.
Methods Used
- Whole-cell biosensor technology.
- Quantification of fucosylated HMOs.
- Adaptation of the platform for specific HMO analysis.
- High-throughput screening techniques.
Main Results
- The method allows for rapid quantification of HMOs.
- Improved signal-to-noise ratio enhances detection accuracy.
- Adaptation for production strain analysis shows promise.
- High-throughput capabilities can accelerate research.
Conclusions
- This method represents a significant advancement in HMO analysis.
- It can streamline research in human milk oligosaccharides.
- Future applications may improve infant nutrition products.
Frequently Asked Questions
Executive Industry Relevance
High-throughput, linkage-specific quantification of fucosylated human milk oligosaccharides (HMOs) addresses a critical bottleneck in bioprocess optimization for glycan-based therapeutics and nutritional products. This biosensor-driven approach enables rapid screening of production conditions and enzyme libraries, directly impacting early discovery and process development inflection points. Enhanced detection throughput and specificity support risk-adjusted portfolio decisions in biotechnological HMO manufacturing.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rapid interrogation of glycosylation pathway engineering hypotheses in microbial hosts.
- Supports functional validation of fucosyltransferase and fucosidase enzyme variants for target specificity.
- Facilitates predictive confidence in linkage-specific HMO biosynthesis for downstream applications.
Screening & Assay Development
- Delivers high-throughput, quantitative readouts for thousands of bioprocess or enzyme conditions per day.
- Standardizes detection of 2'-fucosyllactose and 3-fucosyllactose with linkage specificity using genetically encoded biosensors.
- Enables robust assay reproducibility and scalability for screening production strains and process parameters.
Translational & Preclinical Research
- Aligns glycan production profiles with translational goals for nutritional and therapeutic product development.
- Supports continuity from microbial engineering through preclinical validation of glycan composition.
- Reduces mechanistic ambiguity in glycan structure-function relationships relevant to product efficacy.
Pipeline & Workflow Integration
This biosensor platform integrates from early discovery through lead identification and process optimization in glycan biomanufacturing workflows.
- Discovery Biology: Accelerates hypothesis testing for enzyme specificity and pathway engineering in HMO biosynthesis.
- Screening: Provides rapid, quantitative, and linkage-specific assay outputs for high-throughput evaluation of production conditions.
- Analytics: Generates dose-response and calibration curves to compare glycan yields and linkage fidelity across samples.
- Translational Research: Ensures glycan profiles meet preclinical requirements for nutritional or therapeutic applications.
- Enterprise Reuse: Offers a modular, enzyme-adaptable platform for expanding glycan detection capabilities across R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in glycan structure and yield, supporting target validation and mechanistic de-risking.
- Operational Value: Enables standardized, scalable, and reproducible quantification workflows for bioprocess optimization.
- Strategic Value: Improves go/no-go decision-making and capital allocation by reducing analytical bottlenecks.
- Portfolio Impact: Supports risk-adjusted prioritization of microbial strains and process conditions for advancement.
Implementation Considerations
- Requires expertise in microbial engineering, flow cytometry, and biosensor assay development.
- Needs access to flow cytometry instrumentation and standard molecular biology infrastructure.
- Demands cross-team standardization of sample preparation and lactose removal strategies.
- Adaptable to additional glycan targets by engineering new enzyme specificities.
- Throughput and specificity may be limited by enzyme robustness and sample matrix complexity.
Biopharma FAQs
Chapters in this video
0:04
Title
1:12
Cell Culture
1:53
Measurement of Fluorescence and Limits of Detection
2:46
Detection and Quantification of 2 -FL in a Producer Strain
4:58
Selective Removal of Lactose: Treatment with Commercial Purified β-galactosidase
6:04
Selective Removal of Lactose: Pre-treatment with LacZ+ Strain
6:48
Selective Removal of Lactose: Lactose Precipitation with Ethanol
7:41
Results: Analysis of Fucosylated Human Milk Trisaccharides Using Genetically Encoded Biosensors
9:37
Conclusion
